Inhibitors of the PD-1/PD-L1 pathway counteract this evasion by blocking the interaction between PD-1 and PD-L1, thereby restoring T cell activity and enhancing anti-tumor immune responses, which has led to a marked improvement in the survival rates of patients with various malignant tumors (22). This evidence concerns the gene PDCD1 and cancer.